The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
In the citing paper
“However, despite high initial response rates, complete and long-term remission is only achieved in up to 40% of patients13–16.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [16]
In the citing paper
“Efficacy results seem similar in patients with LBCL treated with CD19 CAR T cells costimulated by 4-1BB instead of CD28, with or without fixing the ratio of CD4:CD8 cells.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Gisselbrecht, C., Glaß, B., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,639
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577-577. abstract.
- Maude SL, Grupp SA, Pulsipher MA, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Haematologica 2017;102:197-198.
Cited by
Sorted by citations
Items 801–900 of 1,010
Galtier, J., Vercellino, L., Chartier, L., Olivier, P., Tabouret-Viaud, C., Mesguich, C., Blasi, R. D., Durand, A., Raffy, L., Gros, F., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280550 · Cited by 41
Choe, J. H., Abdel‐Azim, H., Padula, W. V., & Abou‐El‐Enein, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45956 · Cited by 41
Akhoundova, D., Seipel, K., Bacher, U., Kronig, M.-N., Porret, N. A., Wiedemann, G., Daskalakis, M., & Pabst, T. (2023) · BMC Cancer · doi:10.1186/s12885-023-10824-3 · Cited by 44
McKenna, M., Epperla, N., Ghobadi, A., Liu, J., Lazaryan, A., Ibrahim, U., Jacobson, C. A., Naik, S. G., Nastoupil, L. J., Chowdhury, S. M., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18828 · Cited by 41
Little, J. S., Kampouri, E., Friedman, D. Z. P., McCarty, T. P., Thompson, G. R., Kontoyiannis, D. P., Vázquez, J. A., Baddley, J. W., & Hammond, S. P. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae133 · Cited by 41
Zeng, C., Cheng, J.-L., Li, T.-J., Huang, J., Li, C.-R., Jiang, L.-J., Wang, J., Chen, L.-T., Mao, X., Zhu, L., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.008 · Cited by 38
Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
Petty, A. J., Heyman, B. M., & Yang, Y. (2020) · Cancers · doi:10.3390/cancers12040842 · Cited by 40
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Liu, D., Zhao, X., Tang, A., Xu, X., Liu, S., Zha, L., Ma, W., Zheng, J., & Shi, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188378 · Cited by 44
Immunotherapy Advances for Epithelial Ovarian Cancer
Hartnett, E. G., Knight, J. C., Radolec, M., Buckanovich, R. J., Edwards, R. P., & Vlad, A. (2020) · Cancers · doi:10.3390/cancers12123733 · Cited by 39
Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
Wang, H., Han, P., Qi, X., Li, F., Li, M., Fan, L., Zhang, H., Zhang, X., & Yang, X. (2021) · Cancers · doi:10.3390/cancers13020197 · Cited by 42
CAR-NK Cells from Engineered Pluripotent Stem Cells: Off-the-shelf Therapeutics for all Patients
Lu, S., & Feng, Q. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.21-0135 · Cited by 41
CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
Sabbah, M., Jondreville, L., Lacan, C., Norol, F., Vieillard, V., Roos‐Weil, D., & Nguyen, S. (2022) · Cancers · doi:10.3390/cancers14153839 · Cited by 42
Wudhikarn, K., Tomás, A. A., Flynn, J. R., Devlin, S. M., Brower, J., Bachanová, V., Nastoupil, L. J., McGuirk, J. P., Maziarz, R. T., Oluwole, O. O., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008294 · Cited by 41
Self-citationCuffel, A., Allain, V., Faivre, L., Blasi, R. D., Morin, F., Vercellino, L., Chevalier, M. F., Desnoyer, A., de Jorna, R., Madelaine, I., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007057 · Cited by 40
Zinzani, P. L., Santoro, A., Gritti, G., Brice, P., Barr, P. M., Kuruvilla, J. G., Cunningham, D., Kline, J. P., Johnson, N. A., Mehta–Shah, N., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010254 · Cited by 40
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota, V., Kerschbaum, J. F., Penack, O., Stein, C. M., Arends, C. M., Koenecke, C., Strzelecka, P. M., Kloos, A., Wiegand, L., Lasch, A., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000957 · Cited by 44
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Yang, C., Nguyen, J., & Yen, Y. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00982-8 · Cited by 44
Bellal, M., Malherbe, J., Damaj, G. L., & du Cheyron, D. (2024) · Critical Care · doi:10.1186/s13054-024-04851-0 · Cited by 42
Blüm, P., & Käyser, S. (2024) · Cancers · doi:10.3390/cancers16081599 · Cited by 42
Sesques, P., Kirkwood, A. A., Kwon, M., Rejeski, K., Jain, M. D., Blasi, R. D., Brisou, G., Gros, F., Bras, F. L., Bories, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01579-w · Cited by 40
“Anti-CD19 CAR T cells have dramatically altered the therapeutic armamentarium and the prognosis of patients with R/R LBCL in the last few years [4–9].”
BackgroundWang, L., Fang, C., Kang, Q., Huang, W., Chen, Z., Zhao, W., Wang, L., Wang, Y., Tan, K., Xiao, G., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01105-8 · Cited by 40
“…of TCR clones in vivo originates primarily from clones with elevated gene expression involved in immune-related signaling pathways in infused products, while the dynamics of CAR-T cells in vivo are linked to heightened expression of genes associated with immune response and cytolysis/cytotoxicity.”
Bock, A. M., & Epperla, N. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01702-5 · Cited by 45
“In the initial study of tisa-cel, 92% of patients required bridging therapy, with 30% of enrolled patients discontinuing prior to CAR T-cell infusion due to disease progression [62].”
InfluentialToward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Mylvaganam, G., Yanez, A. G., Maus, M. V., & Walker, B. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02109 · Cited by 38
Chicaybam, L., Abdo, L. D. M., Viegas, M. S., Marques, L. V. C., de Sousa, P., Batista-Silva, L. R., Alves-Monteiro, V., Bonecker, S. T., Monte-Mór, B. D. C. R., & Bonamino, M. (2020) · Gene Therapy · doi:10.1038/s41434-020-0121-4 · Cited by 40
Srour, S. A., Singh, H., McCarty, J. M., Groot, E. D., Huls, H. M., Rondón, G., Qazilbash, M. H., Ciurea, S. O., Bardelli, G., Buck, J. Y., et al. (2020) · Blood · doi:10.1182/blood.2019002920 · Cited by 40
Yang, C., Xie, M., Zhang, K., Liu, H., Liang, A., Young, K. H., & Qian, W. (2020) · Leukemia · doi:10.1038/s41375-020-0913-y · Cited by 40
McDonald, G., Chubukov, V., Coco, J., Truskowski, K., Narayanaswamy, R., Choe, S. E., Steadman, M., Artin, E., Padyana, A. K., Jin, L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0550 · Cited by 37
Berendsen, M. R., Stevens, W. B. C., van den Brand, M., van Krieken, J. H., & Scheijen, B. (2020) · Cancers · doi:10.3390/cancers12123553 · Cited by 40
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Bhoj, V. G., Li, L. Z., Parvathaneni, K., Zhang, Z., Kacir, S., Arhontoulis, D. C., Zhou, K. H., McGettigan-Croce, B., Nuñez-Cruz, S., Gulendran, G., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.012 · Cited by 39
Perica, K., Flynn, J. R., Curran, K. J., Rivere, I., Wang, X., Sénéchal, B., Halton, E. F., Diamonte, C., Pineda, J. P., Bernal, Y. J., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01196-3 · Cited by 42
Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment
Gaggianesi, M., Franco, S. D., Pantina, V. D., Porcelli, G., D’Accardo, C., Verona, F., Veschi, V., Colarossi, L., Faldetta, N., Pistone, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702642 · Cited by 43
Immunomodulatory Drugs for the Treatment of B Cell Malignancies
Ioannou, N., Jain, K., & Ramsay, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168572 · Cited by 41
DLBCL 1L—What to Expect beyond R-CHOP?
Stegemann, M., Denker, S., & Schmitt, C. A. (2022) · Cancers · doi:10.3390/cancers14061453 · Cited by 43
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
Boettcher, M., Joechner, A., Li, Z., Yang, S. F., & Schlegel, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082158 · Cited by 42
Bastos‐Oreiro, M., Gutierrez, A. M., Reguera, J. L., Iacoboni, G., López‐Corral, L., Terol, M. J., Ortiz‐Maldonado, V., Sanz, J., Guerra, L. M., Bailén, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.855730 · Cited by 40
Xia, Y., Zhang, J., Li, J., Zhang, L., Li, J., Fan, L., & Chen, L. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2136748 · Cited by 41
Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Li, Y., Rezvani, K., & Rafei, H. (2023) · Immunological Reviews · doi:10.1111/imr.13255 · Cited by 41
Ogasawara, K., Lymp, J. F., Mack, T. R., Dell’Aringa, J., Huang, C., Smith, J., Peiser, L., & Kostić, A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2561 · Cited by 39
Frontzek, F., Karsten, I. E., Schmitz, N., & Lenz, G. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221103321 · Cited by 40
Recent advances in organotypic tissue slice cultures for anticancer drug development
He, L., & Deng, C. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78997 · Cited by 40
Amidi, Y., Eckhardt, C. A., Quadri, S. A., Malik, P., Firme, M. S., Jones, D. K., Jain, A., Danish, H. H., Rubin, D. B., Jacobson, C. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005459 · Cited by 39
Fergusson, N., Adeel, K., Kekre, N. K., Atkins, H. L., & Hay, K. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1178403 · Cited by 39
Scordo, M., Flynn, J. R., Gönen, M., Devlin, S. M., Parascondola, A., Tomás, A. A., Shouval, R., Brower, J., Porter, D. L., Schuster, S. J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010302 · Cited by 40
Self-citationBrudno, J. N., Natrakul, D. A., Karrs, J. X., Patel, N., Maass‐Moreno, R., Ahlman, M. A., Mikkilineni, L., Mann, J., Stroncek, D. F., Highfill, S. L., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011470 · Cited by 40
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 43
Ahmed, N., Wesson, W., Lutfi, F. U., Porter, D. L., Bachanová, V., Nastoupil, L. J., Perales, M., Maziarz, R. T., Brower, J., Shah, G. L., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012549 · Cited by 39
Self-citationTherapeutic advances in the targeting of ROR1 in hematological cancers
Tigu, A.-B., Munteanu, R. A., Moldovan, C. S., Drulă, R., Kegyes, D., Tomai, R. A., Moisoiu, V., Ghiaur, G., Tomuleasa, C., Einsele, H., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02239-1 · Cited by 39
Jacobson, C. A., Farooq, U., & Ghobadi, A. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0395 · Cited by 39
Development of CAR-T cell therapy for B-ALL using a point-of-care approach
Abdo, L. D. M., Barros, L. R. C., Viegas, M. S., Marques, L. V. C., Ferreira, P. D. S., Chicaybam, L., & Bonamino, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1752592 · Cited by 38
CAR T cells for T-cell leukemias: Insights from mathematical models
Pérez‐García, V. M., León‐Triana, O., Rosa, M., & Pérez‐Martínez, A. (2020) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2020.105684 · Cited by 39
Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells
Mika, T., Maghnouj, A., Klein‐Scory, S., Ladigan‐Badura, S., Baraniskin, A., Thomson, J., Hasenkamp, J., Hahn, S. A., Wulf, G. G., & Schroers, R. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00084 · Cited by 40
Hong, R., Zhao, H., Wang, Y., Chen, Y., Cai, H., Hu, Y., Wei, G., & Huang, H. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01060-5 · Cited by 41
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Noh, J., Seo, H., Lee, J., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218000 · Cited by 40
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
Gurney, M. E., & O'Dwyer, M. E. (2021) · Cancers · doi:10.3390/cancers13071568 · Cited by 41
Schubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
Zinzani, P. L., Rodgers, T. D., Marino, D., Frezzato, M., Barbui, A. M., Castellino, C., Meli, E., Fowler, N. H., Salles, G., Feinberg, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1471 · Cited by 39
Self-citationAssessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
Puglianini, O. A. C., & Chávez, J. C. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s281247 · Cited by 37
Ivica, N. A., & Young, C. M. (2021) · Healthcare · doi:10.3390/healthcare9081062 · Cited by 39
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
Hwang, M. S., Miller, M. S., Thirawatananond, P., Douglass, J., Wright, K. M., Hsiue, E. H.-C., Mog, B. J., Aytenfisu, T. Y., Murphy, M. B., Azurmendi, P. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25605-4 · Cited by 38
Pearson, A. D. J., Rössig, C., Mackall, C. L., Shah, N. N., Baruchel, A., Reaman, G. H., Ricafort, R. J., Heenen, D. L., Bassan, A., Berntgen, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.016 · Cited by 40
CAR-T cells, from principle to clinical applications
Bourbon, E., Ghesquières, H., & Bachy, E. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.017 · Cited by 40
Kedmi, M., Shouval, R., Fried, S., Bomze, D., Fein, J. A., Cohen, Z., Danilesko, I., Shem‐Tov, N., Yerushalmi, R., Jacoby, E., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.02.017 · Cited by 43
Wang, X., Dong, Z., Awuah, D., Chang, W.-C., Cheng, W. A., Vyas, V., Cha, S.-C., Anderson, A., Zhang, T., Wang, Z., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01477-x · Cited by 41
Rejeski, K., Blumenberg, V., Iacoboni, G., López‐Corral, L., Kharboutli, S., Hernani, R., Petrera, A., Müller, N., Hildebrand, F., Frölich, L., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000858 · Cited by 39
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*
Gutierrez, C., Brown, A. R. T., May, H. P., Beitinjaneh, A., Stephens, R. S., Rajendram, P., Nates, J. L., Pastores, S. M., Dharshan, A., de Moraes, A. G., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005149 · Cited by 38
Self-citationChen, A. J., Zhang, J., Agarwal, A., & Lakdawalla, D. N. (2022) · Value in Health · doi:10.1016/j.jval.2022.02.007 · Cited by 38
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 39
Beyond youth: Understanding CAR T cell fitness in the context of immunological aging
Noll, J. H., Levine, B. L., June, C. H., & Fraietta, J. A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101840 · Cited by 41
Smirnov, S., Mateikovich, P., Samochernykh, K. A., & Shlyakhto, E. V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1335424 · Cited by 42
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
Oh, B. L. Z., Vinanica, N., Wong, D., & Campana, D. (2024) · Haematologica · doi:10.3324/haematol.2023.283848 · Cited by 43
Shu, J., Xie, W., Mei, C., Ren, A., Ke, S., Ma, M.-L., Zhou, Z., Hu, Y., & Mei, H. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103229 · Cited by 38
“24,25 Therefore, we believe that these observed adverse events are more likely attributable to patients ’ poor baseline conditions.”
Thiéblemont, C., da Silva, M. G., Leppä, S., Lenz, G., Cottereau, A., Fox, C. P., López‐Guillermo, A., Illidge, T., Jurczak, W. J., Eich, H. T., et al. (2025) · HemaSphere · doi:10.1002/hem3.70207 · Cited by 42
Epperla, N., Badar, T., Szabó, A., Vaughn, J. L., Borson, S., Saini, N. Y., Patel, R. D., Shah, N. N., Hamadani, M., Ahmed, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000102 · Cited by 38
Hayden, P. J., Sirait, T., Koster, L., Snowden, J. A., & Yakoub‐Agha, I. (2019) · Current Research in Translational Medicine · doi:10.1016/j.retram.2019.05.002 · Cited by 38
CAR T-Cell-Associated Neurotoxicity
Rivera, A., May, S., Lei, M. M., Qualls, S., Bushey, K., Rubin, D. B., & Barra, M. E. (2020) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000302 · Cited by 37
Nair, R. K., & Westin, J. R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_10 · Cited by 43
Self-citationBiomarkers in individualized management of chimeric antigen receptor T cell therapy
Du, M., Hari, P., Hu, Y., & Mei, H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00190-8 · Cited by 38
Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective
Sievers, S., Watson, G., Johncy, S., & Adkins, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00885 · Cited by 39
Al-Mansour, M. M., Al‐Foheidi, M., & Ibrahim, E. M. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2103 · Cited by 39
A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy
Cai, C., Tang, D., Han, Y., Shen, E., Abdihamid, O., Guo, C., Shen, H., & Zeng, S. (2020) · Aging · doi:10.18632/aging.104058 · Cited by 38
Dreger, P., Dietrich, S., Schubert, M., Selberg, L., Bondong, A., Wegner, M., Stadtherr, P., Kimmich, C. R., Kosely, F., Schmitt, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003036 · Cited by 38
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
Mančíková, V., & Šmída, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115536 · Cited by 39
Zhang, Y., Li, J., Lou, X., Chen, X., Yu, Z., Kang, L., Chen, J., Zhou, J., Zong, X., YANG, Z. K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.664421 · Cited by 37
Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health
Banerjee, R. K., Shah, N. D., & Dicker, A. P. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.21.00023 · Cited by 38
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
Snyder, S., Chung, K., Jun, M. P., & Gitlin, M. D. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01838-z · Cited by 38
Epstein–Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes
Lindsay, J., Othman, J., Heldman, M. R., & Slavin, M. A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000787 · Cited by 38
Engineered T Cells: CAR T Cell Therapy and Beyond
Johnson, P. C., & Abramson, J. S. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01161-4 · Cited by 39
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
Bock, A. M., Nowakowski, G. S., & Wang, Y. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00925-1 · Cited by 40
Gouni, S., Rosenthal, A. C., Crombie, J. L., Ip, A., Kamdar, M. K., Hess, B. T., Feng, L., Watson, G., Ayers, A. A., Neelapu, S. S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006801 · Cited by 38
Perales, M., Anderson, L. D., Jain, T., Kenderian, S. S., Oluwole, O. O., Shah, G. L., Svoboda, J., & Hamadani, M. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.06.019 · Cited by 39
Makita, S., Imaizumi, K., Kurosawa, S., & Tobinai, K. (2019) · Drugs in Context · doi:10.7573/dic.212567 · Cited by 40
Barriers to antibody therapy in solid tumors, and their solutions
Matsumura, Y. (2021) · Cancer Science · doi:10.1111/cas.14983 · Cited by 38
Shargian, L., Raanani, P., Yeshurun, M., Gafter‐Gvili, A., & Gurion, R. (2022) · British Journal of Haematology · doi:10.1111/bjh.18335 · Cited by 37
Martínez‐Cibrián, N., Español‐Rego, M., Pascal, M., Delgado, J., & Ortiz‐Maldonado, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005457 · Cited by 38
Immunotherapies against human bacterial and fungal infectious diseases: A review
Qadri, H., Shah, A. H., Alkhanani, M., Almilaibary, A., & Mir, M. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1135541 · Cited by 39
RetractedLouie, R. H. Y., Cai, C., Samir, J., Singh, M., Deveson, I. W., Ferguson, J. M., Amos, T. G., McGuire, H. M., Gowrishankar, K., Adikari, T. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43656-7 · Cited by 38
T-cell dysfunctions in myelodysplastic syndromes
Rodríguez‐Sevilla, J. J., & Colla, S. (2024) · Blood · doi:10.1182/blood.2023023166 · Cited by 37
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
Perna, F., Parekh, S. S., Diorio, C. J., Smith, M. M., Subklewe, M., Mehta, R. P., Locke, F. L., & Shah, N. N. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013044 · Cited by 41
Shumilov, E., Wurm‐Kuczera, R., Kerkhoff, A., Wang, M., Melchardt, T., Holtick, U., Bacher, U., Staber, P. B., Mazzeo, P., Leng, C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014903 · Cited by 37
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Locke, F. L., Siddiqi, T., Jacobson, C. A., Nikiforow, S., Ahmed, S., Miklos, D. B., Lin, Y., Lunning, M. A., Hill, B. T., Ghobadi, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013656 · Cited by 37
Metadata
- Authors
- Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., & Maziarz, R. T.
- Affiliations
- The University of Sydney (AU)
- From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent’s Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) — both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell...
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 45-56
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903062212
- Cited by
- 4,112
- References
- 29
- Citations by year
- 2026: 363 · 2025: 507 · 2024: 593 · 2023: 593 · 2022: 693 · 2021: 624 · 2020: 502 · 2019: 218
- FWCI
- 125.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, CD19, autologous stem cell transplantation, cytokine release syndrome, neurological adverse events, relapse-free survival, complete response, immune checkpoint molecules
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
